Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit
Serina Therapeutics (NYSE American: SER) is set to present groundbreaking data on its POZ-lipid technology at the 4th Annual mRNA-Based Therapeutics Summit in Boston, MA, from July 29-31, 2024. Dr. Randall Moreadith, Chief Development Officer, will showcase how this innovative approach could enhance the safety and efficacy of mRNA-LNP formulations.
The presentation, scheduled for July 29 at 9:00 AM ET, will highlight that POZ-lipid does not induce IgM or IgG antibody responses, even with repeated dosing in animal models. This is a significant advancement over current PEG-lipids used in mRNA vaccines, which can trigger anti-PEG antibody responses linked to serious adverse events, including life-threatening anaphylaxis.
Serina's technology has the potential to mitigate these risks, potentially improving the overall safety profile of mRNA-LNP medicines and opening new possibilities in the rapidly evolving field of mRNA therapeutics.
Serina Therapeutics (NYSE American: SER) presenterà dati innovativi sulla sua tecnologia POZ-lipid al 4° Summit Annuale sulle Terapie Basate su mRNA che si terrà a Boston, MA, dal 29 al 31 luglio 2024. Il Dr. Randall Moreadith, Chief Development Officer, illustrerà come questo approccio innovativo potrebbe migliorare la sicurezza e l'efficacia delle formulazioni mRNA-LNP.
La presentazione, prevista per il 29 luglio alle 9:00 AM ET, metterà in evidenza che POZ-lipid non induce risposte anticorpali IgM o IgG, anche con dosaggi ripetuti in modelli animali. Questo rappresenta un progresso significativo rispetto ai PEG-lipidi attualmente utilizzati nei vaccini mRNA, che possono innescare risposte anticorpali anti-PEG collegate a eventi avversi gravi, inclusa l'anaphylassi potenzialmente letale.
La tecnologia di Serina ha il potenziale di mitigare questi rischi, migliorando potenzialmente il profilo di sicurezza complessivo dei medicinali mRNA-LNP e aprendo nuove possibilità nel campo in rapida evoluzione delle terapie mRNA.
Serina Therapeutics (NYSE American: SER) está lista para presentar datos innovadores sobre su tecnología POZ-lipid en la 4ª Cumbre Anual sobre Terapias basadas en mRNA en Boston, MA, del 29 al 31 de julio de 2024. El Dr. Randall Moreadith, Director de Desarrollo, mostrará cómo este enfoque innovador podría mejorar la seguridad y eficacia de las formulaciones de mRNA-LNP.
La presentación, programada para el 29 de julio a las 9:00 AM ET, destacará que POZ-lipid no induce respuestas de anticuerpos IgM o IgG, incluso con dosis repetidas en modelos animales. Esto representa un avance significativo sobre los PEG-lípidos actuales utilizados en las vacunas de mRNA, que pueden desencadenar respuestas de anticuerpos anti-PEG asociadas con eventos adversos graves, incluida la anafilaxis potencialmente mortal.
La tecnología de Serina tiene el potencial de mitigar estos riesgos, mejorando potencialmente el perfil de seguridad general de los medicamentos mRNA-LNP y abriendo nuevas posibilidades en el campo de terapias de mRNA que evoluciona rápidamente.
세리나 치료제(뉴욕증권거래소: SER)는 2024년 7월 29일부터 31일까지 매사추세츠주 보스턴에서 열리는 제4회 mRNA 기반 치료제 서밋에서 독창적인 POZ-lipid 기술에 대한 혁신적인 데이터를 발표할 예정입니다. 랜들 모리디스 박사, 최고 개발 책임자는 이 혁신적인 접근이 mRNA-LNP 제형의 안전성 및 효능을 향상시킬 수 있는 방법을 보여줄 것입니다.
7월 29일 오전 9:00 ET에 예정된 발표에서 POZ-lipid가 반복적인 투여에도 불구하고 IgM 또는 IgG 항체 반응을 유도하지 않는다는 점을 강조할 것입니다. 이는 심각한 부작용을 유발할 수 있는 현재 사용 중인 PEG-lipid에 비해 중요한 발전입니다.
세리나의 기술은 이러한 위험을 완화할 수 있는 가능성이 있으며, mRNA-LNP 약물의 전반적인 안전성 프로필을 개선하고 mRNA 치료의 빠르게 발전하는 분야에서 새로운 가능성을 열어줄 수 있습니다.
Serina Therapeutics (NYSE American: SER) s'apprête à présenter des données révolutionnaires sur sa technologie POZ-lipid lors du 4e Sommet Annuel sur les Thérapeutiques à base d'mRNA à Boston, MA, du 29 au 31 juillet 2024. Le Dr. Randall Moreadith, Responsable du Développement, montrera comment cette approche novatrice pourrait améliorer la sécurité et l'efficacité des formulations mRNA-LNP.
La présentation, prévue pour le 29 juillet à 9h00 ET, soulignera que POZ-lipid n'induit pas de réponse d'anticorps IgM ou IgG, même en cas d'administration répétée chez des modèles animaux. Cela représente une avancée significative par rapport aux PEG-lipides actuellement utilisés dans les vaccins à base d'mRNA, qui peuvent déclencher des réponses d'anticorps anti-PEG liées à des événements indésirables graves, incluant l'anaphylaxie potentiellement mortelle.
La technologie de Serina a le potentiel de mitiger ces risques, pouvant ainsi améliorer le profil de sécurité global des médicaments mRNA-LNP et ouvrir de nouvelles possibilités dans le domaine en évolution rapide des thérapies à base d'mRNA.
Serina Therapeutics (NYSE American: SER) wird auf dem 4. jährlichen mRNA-basierten Therapeutik-Gipfel in Boston, MA, vom 29. bis 31. Juli 2024 wegweisende Daten zu seiner POZ-lipid-Technologie präsentieren. Dr. Randall Moreadith, Chief Development Officer, wird zeigen, wie dieser innovative Ansatz die Sicherheit und Wirksamkeit von mRNA-LNP-Formulierungen verbessern könnte.
Die Präsentation, die für den 29. Juli um 9:00 Uhr ET geplant ist, wird hervorheben, dass POZ-lipid keine IgM- oder IgG-Antikörperantworten induziert, selbst bei wiederholter Dosierung in Tiermodellen. Dies stellt einen signifikanten Fortschritt im Vergleich zu den derzeit in mRNA-Impfstoffen verwendeten PEG-Lipiden dar, die anti-PEG-Antikörperantworten hervorrufen können, die mit schweren unerwünschten Ereignissen, einschließlich lebensbedrohlicher Anaphylaxie, in Verbindung stehen.
Die Technologie von Serina hat das Potenzial, diese Risiken zu mindern und könnte das allgemeine Sicherheitsprofil von mRNA-LNP-Medikamenten verbessern und neue Möglichkeiten im sich schnell entwickelnden Bereich der mRNA-Therapeutika eröffnen.
- None.
- None.
HUNTSVILLE, July 29, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ PlatformTM drug delivery technology, today announced that Randall Moreadith, MD, Ph.D., Chief Development Officer, will present at the 4th Annual mRNA-Based Therapeutics Summit. The conference will take place from July 29-31, 2024, in Boston, MA.
Dr. Moreadith's presentation, titled "Overcoming Anti-PEG Antibody Responses to Increase Potency & Decrease Adverse Side Effects of mRNA-LNP Formulations”, is scheduled for 9:00 AM ET on Monday, July 29. In this talk, Dr. Moreadith will present novel data on Serina Therapeutics' innovative POZ-lipid, a proprietary technology that aims to significantly advance the safety and efficacy of mRNA-LNP formulations. These data show that POZ-lipid does not induce an IgM or IgG antibody response, even with repeated dosing in in vivo models.
This finding is crucial because the PEG-lipids currently used in mRNA vaccines can elicit an anti-PEG antibody response. This response is associated with serious adverse events, including anaphylaxis, which can pose a life-threatening risk to patients. The presentation will provide insights into how Serina's POZ-lipid technology can potentially mitigate these adverse effects, thereby enhancing the safety and efficacy profile of mRNA-LNP medicines.
Conference Details:
Event: 4th Annual mRNA-Based Therapeutics Summit “Turbocharging New Frontiers of mRNA Medicine to Patients Faster”
Date: July 29-31, 2024
Location: Boston, MA
Presentation Title: "Overcoming Anti-PEG Antibody Responses to Increase Potency & Decrease Adverse Side Effects of mRNA-LNP Formulations”
Presenter: Randall Moreadith, MD, PhD, Chief Development Officer, Serina Therapeutics, Inc.
Time: 9:00 AM ET, Monday, July 29
For more information about the conference and to view the agenda, please visit mRNA-Based Therapeutics Summit Agenda.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases, cancer, and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.
For more information, please visit https://serinatherapeutics.com.
Cautionary Statement Regarding Forward-Looking Statement
This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management’s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina’s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in Serina’s Annual Report on Form 10-K for the year ended December 31, 2023, Serina’s Current Report on Form 8-K that was filed with the SEC on April 1, 2024, and Serina’s other periodic reports and documents filed from time to time with the SEC.
The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
For inquiries, please contact:
Investor.relations@serinatherapeutics.com
(256) 327-9630
FAQ
What is Serina Therapeutics presenting at the 4th Annual mRNA-Based Therapeutics Summit?
When and where is Serina Therapeutics' presentation at the mRNA summit?
What are the key benefits of Serina Therapeutics' POZ-lipid technology for mRNA vaccines?
Who is presenting Serina Therapeutics' data at the mRNA summit?
How might Serina Therapeutics' POZ-lipid technology impact the future of mRNA medicines?
